BCDA BioCardia

BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

SAN CARLOS, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies today announced that Peter Altman, Ph.D., Biocardia’s Chief Executive Officer will give a virtual corporate presentation at the LD Micro 500 taking place online on Tuesday, September 1, 2020 at 10:20 AM ET followed by a live question and answer session with registered investors and other conference attendees.

Webcast link:

In addition, Dr. Altman will be available for virtual one-on-one meetings beginning on September 1, 2020 and through September 4, 2020.  To schedule a meeting, please contact Eric Lahiji at .

About BioCardia

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit .

Media Contact:

Michelle McAdam, Chronic Communications, Inc.



(310) 902-1274

Investor Contact:

David McClung, Chief Financial Officer



(650) 226-0120

EN
26/08/2020

Underlying

BCDABioCardia

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCardia

 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare...

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025. Dr. Altman will sh...

May 21, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Reports First Quarter 2025 Business Highlights and Financial...

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s forma...

May 14, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia to Host Q1 2025 Corporate Update and Financial Results Confe...

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the conferenc...

May 9, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Initiates Patient Enrollment at University of Wisconsin at M...

BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) and Elevated Markers of Cardiac Stress Dr. Amish Raval, Professor of Medicine at the University of Wisconsin School of Medicine and Public Health, to serve as Site Principal Investigator and Co-National Principal Investigator SUNNYVALE, Calif., May 06, 2025 (GLOBE NEWSWIRE) --   [Nasdaq: BCDA], a global leader in cellular...

May 6, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Announces First Patient in Phase 3 Randomized Controlled Dou...

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the first patient enrolled in the Phase III randomized procedure placebo-controlled double-blind CardiAMP HF II clinical trial of the Company’s lead autologous cell therapy program for the treatment of...

May 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch